Chinese Brands Are Taking Over Brazil — And It's Just Getting Started 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Lumentum Holdings Rides AI Wave With Order Book Filled Through 2028 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
Pilots Fear Retaliation for Refusing Middle East Flights Amid Ongoing Conflict 
Anthropic's Mythos AI Model Sparks Emergency Cybersecurity Meeting With Top U.S. Bank CEOs 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
San Francisco Suspect Arrested After Molotov Cocktail Attack on OpenAI CEO Sam Altman's Home 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
Foreign Investors Pour $18.65 Billion into Japanese Stocks Amid Market Stabilization 
Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
SEATTLE, Feb. 14, 2017 -- Nohla Therapeutics Inc. (Nohla), a leading innovator in the development of universal donor cellular therapies for the treatment of patients with blood cancers, announced today that it will present at the Cowen and Company 37th Annual Health Care Conference in Boston, MA. Dr. Colleen Delaney, Nohla’s Scientific Founder and Chief Medical Officer, is scheduled to present on Tuesday, March 7th at 2:00pm ET.
Dr. Delaney’s presentation will provide an overview of the Company’s ex vivo expansion platform, which enables expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). In addition, Dr. Delaney will profile Nohla’s two lead programs evaluating the ability of these products to reduce infection and other complications of neutropenia in multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML).
About Nohla Therapeutics
Nohla Therapeutics Inc. (Nohla) is a clinical stage company dedicated to the development of universal donor cellular therapies for the treatment of patients with life threatening blood cancers. The Company is leveraging a platform developed over the past two decades at Fred Hutchinson Cancer Research Center which enables the ex vivo expansion and directed differentiation of cord blood stem/progenitor cells resulting in “off-the-shelf” universal donor cellular therapies (which can be used on demand without the need for HLA matching). Nohla is evaluating the ability of these “off-the-shelf” cryopreserved expanded cell products to reduce infection and other complications of neutropenia in several clinical settings including two lead programs involving multi-center, randomized clinical trials: a Phase IIb study in the setting of cord blood transplant and a global Phase II study in the setting of high dose chemotherapy for acute myelogenous leukemia (AML). Nohla is supported by top-tier healthcare dedicated institutional investors including ARCH Venture Partners, 5AM Ventures, and Jagen Group.
For more information, please contact: Investors Candice Knoll Blueprint Life Science Group +1 415-375-3340 Ext. 4 [email protected] Media Esther Cuno Director, Corporate Communications +1 206 519 5313 [email protected]
